Global Itraconazole API Market Size, Trends & Analysis - Forecasts to 2026 By Type of Drug (Generic & Brand), By Application Site (Toenails & Fingernails, Lungs, Mouth & Throat), By Route of Administration (Oral & Intravenous), By Type of Fungal Infection (Aspergillosis, Blastomycosis, Coccidioidomycosis, Histoplasmosis, Paracoccidioidomycosis, Sporotrichosis, and Onychomycosis), By Region (Europe, North America, MEA, Asia Pacific, and CSA); Vendor Landscape, Company Market Share Analysis, End-User Landscape, and Competitor Analysis
Itraconazole API Market Insights
The Itraconazole API market will rise at a CAGR assessment of 3.5% during the figure season of 2020-2026. It is antifungal to treat various types of fungal infections such as Aspergillosis, Coccidioidomycosis, Blastomycosis, Paracoccidioidomycosis, and Histoplasmosis. Such infection can affect the mouth, throat, lungs, other organs superficially connected with lungs, nails, etc. Hence, rising cases of patients suffering from the fungal infection will propel the growth of this drug market. On the other hand, the patients suffering from low immunity-related disorders have a high chance of acquiring opportunistic infection which can propel drug adoption in the market. Also, fungal infection being the most common type of infection amongst various patients, and Itraconazole being the most preferred API drug for the first line of treatment of such type of fungal infection, the market will have a moderate growth rate during the forecast period.
Itraconazole API Market: By Type for Drug
The market has both generic and branded Itraconazole API drugs. The conventional medications/ generic will have more share in the overall industry when contrasted with the branded medications. Besides, generic drug sales will grow faster in the Asia-Pacific region.
Itraconazole API Market: By Application Site
Based on the site of infection, this market can be segmented as mouth & throat, lungs, and toe & fingernail infection. The mouth & throat infection segment will contribute the most in terms of revenue value and sale of the drug in the market during the forecast period. A high prevalence of throat infection among most of the patients suffering from some form of infectious disease will affect the market positively.
Itraconazole API Market: By Route of Administration
The market can be bifurcated into intravenous administration and oral intake of drugs as per the route of intake is considered. The oral administration or the Itraconazole capsule sale is analyzed to have the largest share in the market owing to the availability, cost, and type of patient location for the fungal treatment.
Itraconazole API Market: By Type of Fungal Infection
Based on the type of fungal infection affecting the body, the market can be well explained in 7 segments, namely Aspergillosis, Blastomycosis, Coccidioidomycosis, Histoplasmosis, Paracoccidioidomycosis, Sporotrichosis, and Onychomycosis. The Aspergillosis segment will be the highest contributor in terms of revenue sale in the market owing to its extreme prevalence in the throat infection. Moreover, Itraconazole is the most preferred API drug for the first line of treatment of such type of fungal infection.
Itraconazole API Market: By Region
The geographical analysis segment of the Itraconazole API Market includes Middle East & Africa, CSA, North America, Asia-Pacific, and Europe. US and Canada being the highly prevalent country with fungal infections make the North American region as a whole the major share contributor in the market during the forecast period. However, Asia Pacific will be a hub of opportunities for various API drug manufacturers, owing to the high drug penetration trend, majorly due to the extensive incidence of lung infection, especially in IPD patients in the coming years.
Itraconazole API Market Share and Competitor Analysis
Major companies in the market are Sandoz, Mylan N.V., Zydus, Amneal Pharmaceuticals, Inc., Par Pharmaceutical, Accord Healthcare, Strides Pharma Science Limited, Alembic Pharmaceuticals Ltd., Apotex Inc., Alkem Laboratories Limited., Torrent Pharmaceuticals Ltd., Annora Pharma Pvt. Ltd., Sebela Pharmaceuticals Inc., Janssen Pharmaceuticals, Inc., Mayne Pharma, Albemarle Corporation,Nosch Labs Private Limited, Asia Pioneer Pharmaceuticals, Nosch Labs Pvt. Ltd., Quimica Sintetica S.A., Tenatra International, Metrochem API Private Limited, Aspire Group, Beaukev Pharma International Pvt.Ltd., GPT Pharmaceuticals Pvt. Ltd., and Hetero among others.
Please note: This is not an exhaustive list of companies profiled in the report.
In December 2018, Mayne Pharma got FDA endorsement of Tolsura (SUBA-itraconazole containers) for the treatment of parasitic diseases.
Check the Press Release on Global Itraconazole API Market Report
We value your investment and offer free customization with every report to fulfil your exact research needs.
The Global Itraconazole API Market has been studied from the year 2017 till 2026. However, the CAGR provided in the report is from the year 2018 to 2026. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.
The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply side analysis for the Itraconazole API Market.
The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.
Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the companies and customer analytics.
Tailor made solutions just for you
80% of our clients seek made-to-order reports. How do you want us to tailor yours?